Publications Oral Janus Kinase Inhibitors for Maintenance of Remission in Ulcerative Colitis Citation Davies SC, Hussein IM, Nguyen TM, Parker CE, Khanna R, Jairath V. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020 Jan 27;1(1):CD012381. doi: 10.1002/14651858.CD012381.pub2. PMID: 31984480; PMCID: PMC6984444. Abstract Background: Tofacitinib is an oral Janus kinase (JAK) inhibitor which blocks cytokine signaling involved in the pathogenesis of autoimmune diseases including ulcerative colitis (UC). The etiology of UC is poorly understood, however research suggests the development and progression of the disease is due to a dysregulated immune response leading to inflammation of the colonic mucosa in genetically predisposed individuals. Additional medications are currently required since some patients do not respond to the available medications and some medications are associated with serious adverse events (SAEs). JAK inhibitors have been widely studied in diseases including rheumatoid arthritis and Crohn’s disease and may represent a promising and novel therapeutic option for the treatment of UC. Tags Drug Therapy, Janus kinase inhibitors, Maintenance Chemotherapy, Piperidines, Protein Kinase Inhibitors, Pyrimidines, Pyrroles, therapeutic use, Ulcerative Colitis Read More